Enabling the Nervous System

to Repair Itself

We create innovative treatments for

nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are Alzheimer’s disease, spinal cord injury and multiple sclerosis.

In the US Alone:


People Living with Spinal Cord Injury1


People Living with MS2


People Living with Alzheimer’s3

1. National Spinal Cord Injury Statistical Center, 2021 Fact Sheet

2. National Multiple Sclerosis Society

3. Alzheimer’s Association

Midas Letter

“I have never seen a biotech investment company even come close to it.
NervGen has the potential for mind blowing yields!”

Dr. Mark Swaim
BioPub Editor in Chief

Play Video

The NervGen Story

In this inspiring and heartfelt video, Dr. Jerry Silver, Professor of Neurosciences, Case Western Reserve University, shares his journey and how the research carried out in his lab led to the formation of NervGen.

The video highlights how NervGen is developing Dr. Silver’s foundational discoveries into a disruptive technology that is aimed at changing the paradigm of how nervous system damage will be treated.

Play Video

Dramatic Pre-Clinical Outcomes

Dramatic pre-clinical studies 

Featured Press Releases

Key Investment Highlights

  • NervGen’s lead product, NVG-291, is the only drug of its kind in clinical development
  • Phase 1 clinical trials are underway in using NVG-291 to treat nerve damage in Alzheimer’s disease, multiple sclerosis (MS) and spinal cord injury.
  • Dramatic and unprecedented results have been achieved in preclinical animal trials
  • NVG-291 is the brainchild of world-renowned neuroscientist Dr. Jerry Silver and has been in development for over two decades.

Key Upcoming Value Drivers

  • Key Upcoming Value Drivers

    • Initiate clinical trials in patients (H2 2022)

    – Phase 2a in spinal cord injury

    – Phase 2 in MS – Phase 1b/2a in Alzheimer’s disease

    • Awarding of DoD sponsored grants and related DoD collaborations (2022)

    • Awarding of privately funded grants – core and additional indications (2022)

    • Up-listing from OTCQX to Nasdaq (H1, 2022)

Industry Benchmarks

3 headlines for Comparables

Investor Inquiries

Huitt Tracey

Corporate Communications
(604) 362-6209


Nancy Thompson

Vorticom, Inc.
(212) 532-2208